OP78 EGFR mutations based on circulating free DNA (cfDNA) in the subset of Japanese patients (pts) from IPASS (IRESSA Pan ASia Study), a Phase III study of first-line gefitinib (G) vs carboplatin/paclitaxel (C/P) in clinically selected patients with advanced non-small-cell lung cancer (NSCLC)

N. Yamamoto; Y. Ichinose; Y. Nishiwaki; Y. Ohe; K. Nishio; H. Jiang; E. Duffield; N. Saijo; T. Mok; M. Fukuoka

doi:10.1016/s1359-6349(09)72138-x

OP78 EGFR mutations based on circulating free DNA (cfDNA) in the subset of Japanese patients (pts) from IPASS (IRESSA Pan ASia Study), a Phase III study of first-line gefitinib (G) vs carboplatin/paclitaxel (C/P) in clinically selected patients with advanced non-small-cell lung cancer (NSCLC)

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(09)72138-x ◽

2009 ◽

Vol 7 (4) ◽

pp. 10 ◽

Cited By ~ 1

Author(s):

N. Yamamoto ◽

Y. Ichinose ◽

Y. Nishiwaki ◽

Y. Ohe ◽

K. Nishio ◽

...

Keyword(s):

Lung Cancer ◽

Japanese Patients ◽

Small Cell ◽

Phase Iii ◽

Egfr Mutations ◽

Small Cell Lung ◽

First Line ◽

Circulating Free Dna ◽

Free Dna ◽

Phase Iii Study

Download Full-text

Phase III study of gefitinib (G) versus gefitinib+carboplatin+pemetrexed (GCP) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009)

Annals of Oncology ◽

10.1093/annonc/mdy292.005 ◽

2018 ◽

Vol 29 ◽

pp. viii496 ◽

Cited By ~ 6

Author(s):

M. Seike ◽

A. Inoue ◽

S. Sugawara ◽

S. Morita ◽

Y. Hosomi ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Egfr Mutations ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Phase Iii Study ◽

First Line Treatment

Download Full-text

9LBA A randomized phase III study comparing gefitinib with carboplatin (CBDCA) plus paclitaxel (TXL) for the first-line treatment of non-small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ002 study

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(09)72038-5 ◽

2009 ◽

Vol 7 (3) ◽

pp. 6 ◽

Cited By ~ 7

Author(s):

A. Inoue ◽

K. Kobayashi ◽

M. Maemondo ◽

S. Sugawara ◽

S. Oizumi ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Egfr Mutations ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Phase Iii Study ◽

First Line Treatment

Download Full-text

Epidermal Growth Factor Receptor Mutation Status in Circulating Free DNA in Serum: From IPASS, a Phase III Study of Gefitinib or Carboplatin/Paclitaxel in Non-small Cell Lung Cancer

Journal of Thoracic Oncology ◽

10.1097/jto.0b013e3182307f98 ◽

2012 ◽

Vol 7 (1) ◽

pp. 115-121 ◽

Cited By ~ 135

Author(s):

Koichi Goto ◽

Yukito Ichinose ◽

Yuichiro Ohe ◽

Nobuyuki Yamamoto ◽

Shunichi Negoro ◽

...

Keyword(s):

Lung Cancer ◽

Growth Factor Receptor ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Mutation Status ◽

Circulating Free Dna ◽

Free Dna ◽

Phase Iii Study ◽

Epidermal Growth

Download Full-text

6519 ORAL Favorable benefit to risk profile for pemetrexed plus cisplatin versus gemcitabine plus cisplatin in a large phase III study of first-line therapy in advanced non-small cell lung cancer

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(07)71347-2 ◽

2007 ◽

Vol 5 (4) ◽

pp. 363 ◽

Cited By ~ 2

Author(s):

G. Scagliotti ◽

K. Park ◽

S. Patil ◽

J. Rolski ◽

T. Gorksel ◽

...

Keyword(s):

Lung Cancer ◽

Risk Profile ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Phase Iii Study ◽

Large Phase

Download Full-text

Prognostic Factors in Non-Small-Cell Lung Cancer (NSCLC) Patients with Epidermal Growth Factor Receptor (EGFR) Mutations: Data from the Randomized Phase III Study Compared Gefitinib with Carboplatin Plus Paclitaxel (NEJ002)

Annals of Oncology ◽

10.1016/s0923-7534(20)32317-6 ◽

2012 ◽

Vol 23 ◽

pp. xi116

Author(s):

Y. Minegishi ◽

K. Kobayashi ◽

M. Maemondo ◽

A. Inoue ◽

S. Sugawara ◽

...

Keyword(s):

Lung Cancer ◽

Epidermal Growth Factor Receptor ◽

Growth Factor Receptor ◽

Small Cell ◽

Phase Iii ◽

Egfr Mutations ◽

Small Cell Lung ◽

Phase Iii Study ◽

Epidermal Growth ◽

Nsclc Patients

Download Full-text

A randomized, multicenter phase III study of lobaplatin/etoposide versus cisplatin/etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer and circulating tumor cells (CTCs) as an exploratory biomarker.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.7595 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 7595-7595 ◽

Cited By ~ 2

Author(s):

Ying Cheng ◽

Yun Fan ◽

Xiaoqing Liu ◽

Yunpeng Liu ◽

Jiwei Liu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

First Line ◽

First Line Therapy ◽

Multicenter Phase ◽

Line Therapy ◽

Phase Iii Study ◽

Extensive Stage

Download Full-text

PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung Cancer

Journal of Thoracic Oncology ◽

10.1097/jto.0000000000000366 ◽

2015 ◽

Vol 10 (1) ◽

pp. 134-142 ◽

Cited By ~ 75

Author(s):

Ralph G. Zinner ◽

Coleman K. Obasaju ◽

David R. Spigel ◽

Robert W. Weaver ◽

J. Thaddeus Beck ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

Phase Iii Study

Download Full-text

PD4-2-3: Global Lung Oncology Branch trial 3 (Glob 3): final results of a randomised multinational Phase III study of oral and i.v. vinorelbine (NVB) plus cisplatin (CDDP) versus docetaxel (DTX) plus CDDP as first-line treatment for advanced Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology ◽

10.1097/01.jto.0000283381.78585.f2 ◽

2007 ◽

Vol 2 (8) ◽

pp. S451

Author(s):

Eng-Huat Tan ◽

Tomasz Grodzki ◽

Claus-Peter Schneider ◽

Peter Zatloukal ◽

Martin Reck ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Phase Iii Study ◽

First Line Treatment

Download Full-text

Subgroup Analysis of Japanese Patients in a Phase III Study of Atezolizumab in Extensive-stage Small-cell Lung Cancer (IMpower133)

Clinical Lung Cancer ◽

10.1016/j.cllc.2019.07.005 ◽

2019 ◽

Vol 20 (6) ◽

pp. 469-476.e1 ◽

Cited By ~ 5

Author(s):

Makoto Nishio ◽

Shunichi Sugawara ◽

Shinji Atagi ◽

Hiroaki Akamatsu ◽

Hiroshi Sakai ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Subgroup Analysis ◽

Japanese Patients ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Phase Iii Study ◽

Extensive Stage

Download Full-text

FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC)

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.3 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 3-3 ◽

Cited By ~ 70

Author(s):

R. Pirker ◽

A. Szczesna ◽

J. von Pawel ◽

M. Krzakowski ◽

R. Ramlau ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Multicenter Phase ◽

Phase Iii Study ◽

First Line Treatment

Download Full-text